Stran 1 iz 23 rezultatov
BACKGROUND
Data on the effects of folic acid supplementation on clinical symptoms and metabolic profiles of patients with endometrial hyperplasia (EH) are limited. This investigation was performed to evaluate the effects of folic acid supplementation on clinical symptoms and metabolic status of
BACKGROUND
Several previous studies have examined the effect of CYP2D6 gene polymorphism on the efficacy and metabolism of tamoxifen (Tamoxifen Teva, Nolvadex) in the treatment of breast cancer. In the present study, the metabolic profiles associated with various CYP2D6 genotypes were
This 2-year study compared Mesigyna(R) administered to 49 pre-menopausal women between 38 and 50 years, to 99 women fitted with an IUD (Nova-T). A complete lipoprotein assessment was carried out before treatment and at 6, 12, and 24 months of treatment. A bone densitometry was performed on half of
OBJECTIVE
To determine the metabolic effects and efficacy of high-dose continuous megestrol acetate administration in the treatment of endometrial pathology.
METHODS
27 women with histologically proven endometrial pathology (endometrial hyperplasia and irregularly proliferative endometrium) were
OBJECTIVE
The purpose of this multicenter, double-blind, randomized, parallel-group study was to determine the effect of thirteen 28-day cycles of drospirenone combined with estradiol, compared with estradiol alone, on the endometrium of postmenopausal women.
METHODS
Postmenopausal women not on
Selective estrogen receptor modulators are a growing class of nonsteroidal compounds with estrogen-like actions in bone, lipid metabolism, and antiestrogenic actions in the breast. Tamoxifen and its derivatives have a weak estrogenic action in the uterus and are responsible for endometrial
OBJECTIVE
To compare the effect of continuous norethindrone acetate (NA)-ethinyl estradiol (EE2) combinations with matching unopposed EE2 or placebo.
METHODS
A 2-year, double-blind, placebo-controlled, parallel-group clinical trial.
METHODS
Outpatients at 65 centers.
METHODS
Asymptomatic or mildly
OBJECTIVE
The clinical and endometrial efficacy and lipid response of two different doses of intrauterine levonorgestrel were assessed in comparison with sequential oral medroxyprogesterone acetate in postmenopausal women receiving continuous oral E2-valerate.
METHODS
One-year prospective
OBJECTIVE
To assess the effects of continuous administration of conjugated estrogen combined with sequential administration of medrogestone on lipid profiles, climateric symptoms and endometrial tolerance.
METHODS
This multicenter open study was conducted for one year to assess the effects of a
Oocyte depletion and ovarian aging results in profound alterations at the biological level. The reduction in numbers of follicles leads to reduction of circulating inhibin and increased serum FSH, characteristic marker of ovarian failure. The remaining follicles are overstimulated and premature
A total of 113 women who presented with climacteric symptoms participated in the study. They were randomly allocated to seven groups of 10-27 subjects, who received for 6 mth the following therapies, respectively: conjugated oestrogens (CE) 0.625 mg/day for 21 days + norethisterone (NET) 5 mg/day
OBJECTIVE
We tested a new hormone replacement formulation based on the hypothesis that interrupted administration of progestin in the presence of continuous estrogen would result in receptor up-regulation and resensitization of target tissues to both estrogen and progestin. As a result, symptom
Transdermal systems for oestrogen therapy in the menopause have become very popular. The compliance, however, is impeded by the cyclic addition of oral progestins which leads to monthly withdrawal bleeds. In this pilot study a skin patch releasing 0.05 mg oestradiol and 0.25 mg norethisterone
BACKGROUND
To compare the effects of continuous combined hormone replacement therapy (Kliogest) and placebo on climacteric symptoms, bone turnover markers, serum lipid profiles and the safety of Kliogest.
METHODS
This is a 4-month, single-centre, double-blind, placebo-controlled clinical study.
New oral contraceptives (OC) with lower estrogen contents are potentially useful for menopausal replacement. An OC with 20 micrograms ethinyl estradiol and 150 micrograms desogestrel was used for this purpose in perimenopausal women with climacteric syndrome. The treated group (N = 30), was given OC